Literature DB >> 33965454

Controlling healthcare-associated transmission of SARS-CoV-2 variant of concern 202012/01 in a large hospital network.

C Duverger1, V Souyri2, C Monteil2, S Fournier2.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33965454      PMCID: PMC8102385          DOI: 10.1016/j.jhin.2021.04.031

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


× No keyword cloud information.
Sir, Many hospital outbreaks of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have been reported worldwide, involving patients and/or healthcare workers (HCWs) [1,2]. Variant of concern 202012/01 (VOC-202012/01) lineage B.1.1.7, responsible for an important epidemic resumption in the UK in November 2020, seems to be more transmissible [3] and more lethal [4] than the pre-existing SARS-CoV-2 variants (non-VOC). In the current context of the emergence of this new variant in France [5], the aim of this observational study was to assess whether transmission control measures were effective to control hospital VOC-202012/01 outbreaks. Assistance publique-Hôpitaux de Paris (AP-HP) is a network of 38 university-affiliated public hospitals, spread over Paris and its suburbs, with a total of 20,000 beds and employing 100,000 HCWs. The coronavirus disease 2019 (COVID-19) transmission prevention strategy is based on universal (HCWs and patients) continuous use of medical masks, use of FFP2 masks during aerosol-generating procedures, contact and droplet precautions in suspected or confirmed cases of COVID-19, limitation of the number of visitors per patient (one visitor/day), and screening of any patients admitted to hospital and any HCWs or patients with symptoms that may be COVID-19 related. Social distancing during breaks (especially meals) is also promoted. HCWs and patients experiencing contact with a confirmed COVID-19 case without wearing a medical mask are tested for SARS-CoV-2, even if asymptomatic, with repeated screening on Day 7. Outbreak control measures include weekly screening of asymptomatic contacts (patients and/or HCWs), cohorting of patient cases and furloughing HCW cases for 10 days, stopping visits and joint activities, and reinforcing COVID-19 prevention transmission measures. A case was defined as any patient or HCW with a positive result on SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) assay. A VOC-202012/01 case was defined as any case with specific mutations identified through specific RT-PCR or genotyping of the spike protein gene [6]. An outbreak was defined as at least two cases (patients and/or HCWs) linked by time (within 7 days), geographic location and possible contact. An outbreak was considered to be controlled after 14 days without any new cases. For each outbreak from 20th December 2020 (first outbreak of VOC-202012/01 in AP-HP hospitals) to 21st February 2021, the following data were collected: variant type, number of cases in patients and HCWs, and outbreak duration (time between first and last cases). The number of cases and the outbreak duration in the non-VOC and VOC-202012/01 groups were compared using the Wilcoxon rank sum test (P=0.05). Analyses were performed using R Version 4.0.3. Among the 218 outbreaks identified during this period (145 non-VOC and 73 VOC-202012/01), 1013 patients and 1166 HCWs were involved. The median number of cases involved in outbreaks was 7.0 [interquartile range (IQR) 4.0–14.0] and 6.0 [IQR 3.0–12.5] in non-VOC and VOC-202012/01 outbreaks, respectively (P=0.35) (Figure 1 ). The median number of patients was 3.0 (IQR 0.0–8.0) in non-VOC outbreaks and 2.0 (IQR 0–6.5) in VOC-202012/01 outbreaks (P=0.23), and the median number of HCWs was 4.0 (IQR 2.0–7.5) in non-VOC outbreaks and 5.0 (IQR 2.0–7.5) in VOC-202012/01 outbreaks (P=0.54). The median outbreak duration was 10.0 (IQR 5.5–19.0) and 9.0 (IQR 5.0–15.5) days in non-VOC and VOC-202012/01 outbreaks, respectively (P=0.41) (Figure 1).
Figure 1

Comparison of the number of cases and duration in hospital outbreaks of pre-existing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants [non-variants of concern (non-VOC)] and SARS-CoV-2 VOC-202012/01. Horizontal lines on the violin plots correspond from bottom to top of box: 25th, 50th and 75th percentiles. The whiskers extend to the minimum and maximum values. In addition, a rotated kernel density plot on each side shows peaks in the data.

Comparison of the number of cases and duration in hospital outbreaks of pre-existing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants [non-variants of concern (non-VOC)] and SARS-CoV-2 VOC-202012/01. Horizontal lines on the violin plots correspond from bottom to top of box: 25th, 50th and 75th percentiles. The whiskers extend to the minimum and maximum values. In addition, a rotated kernel density plot on each side shows peaks in the data. This study had several limitations, including the lack of sequencing completeness. Another limitation is that HCW compliance with the prevention measures was not assessed, and may have been more rigorous with VOC-202012/01 cases, although the time frame in which the sequencing results were available makes this unlikely. In contrast, contact screening of exposed HCWs and patients may have been more extensive due to the fear of rapid dissemination of VOC-202012/01, and this could have explained a higher number of cases in VOC-202012/01 outbreaks, thus reinforcing that the transmission of VOC was not higher than the transmission of non-VOC in this hospital network. Unfortunately, the numbers of screened individuals in both groups are not known. Finally, despite its higher transmissibility and its rapid spread in France, these results suggest that VOC-202012/01 was not associated with higher intrahospital diffusion compared with non-VOC in the hospital network, thanks to strict infection control measures.
  6 in total

Review 1.  Nosocomial transmission and outbreaks of coronavirus disease 2019: the need to protect both patients and healthcare workers.

Authors:  Mohamed Abbas; Tomás Robalo Nunes; Romain Martischang; Walter Zingg; Anne Iten; Didier Pittet; Stephan Harbarth
Journal:  Antimicrob Resist Infect Control       Date:  2021-01-06       Impact factor: 4.887

2.  Transmission of SARS-CoV-2 among healthcare workers and patients in a teaching hospital in the Netherlands confirmed by whole-genome sequencing.

Authors:  S Paltansing; R S Sikkema; S J de Man; M P G Koopmans; B B Oude Munnink; P de Man
Journal:  J Hosp Infect       Date:  2021-02-08       Impact factor: 3.926

3.  Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study.

Authors:  Dan Frampton; Tommy Rampling; Aidan Cross; Heather Bailey; Judith Heaney; Matthew Byott; Rebecca Scott; Rebecca Sconza; Joseph Price; Marios Margaritis; Malin Bergstrom; Moira J Spyer; Patricia B Miralhes; Paul Grant; Stuart Kirk; Chris Valerio; Zaheer Mangera; Thaventhran Prabhahar; Jeronimo Moreno-Cuesta; Nish Arulkumaran; Mervyn Singer; Gee Yen Shin; Emilie Sanchez; Stavroula M Paraskevopoulou; Deenan Pillay; Rachel A McKendry; Mariyam Mirfenderesky; Catherine F Houlihan; Eleni Nastouli
Journal:  Lancet Infect Dis       Date:  2021-04-12       Impact factor: 25.071

4.  Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021.

Authors:  Alexandre Gaymard; Paolo Bosetti; Adeline Feri; Gregory Destras; Vincent Enouf; Alessio Andronico; Sonia Burrel; Sylvie Behillil; Claire Sauvage; Antonin Bal; Florence Morfin; Sylvie Van Der Werf; Laurence Josset; François Blanquart; Bruno Coignard; Simon Cauchemez; Bruno Lina
Journal:  Euro Surveill       Date:  2021-03

5.  Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.

Authors:  Sam Abbott; Rosanna C Barnard; Christopher I Jarvis; Adam J Kucharski; James D Munday; Carl A B Pearson; Timothy W Russell; Damien C Tully; Alex D Washburne; Tom Wenseleers; Nicholas G Davies; Amy Gimma; William Waites; Kerry L M Wong; Kevin van Zandvoort; Justin D Silverman; Karla Diaz-Ordaz; Ruth Keogh; Rosalind M Eggo; Sebastian Funk; Mark Jit; Katherine E Atkins; W John Edmunds
Journal:  Science       Date:  2021-03-03       Impact factor: 63.714

6.  Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study.

Authors:  Robert Challen; Ellen Brooks-Pollock; Jonathan M Read; Louise Dyson; Krasimira Tsaneva-Atanasova; Leon Danon
Journal:  BMJ       Date:  2021-03-09
  6 in total
  2 in total

1.  SARS-CoV-2 in hospital air as revealed by comprehensive respiratory viral panel sequencing.

Authors:  Nazima Habibi; Saif Uddin; Montaha Behbehani; Nasreem Abdul Razzack; Farhana Zakir; Anisha Shajan
Journal:  Infect Prev Pract       Date:  2021-12-27

2.  Bacterial and fungal communities in indoor aerosols from two Kuwaiti hospitals.

Authors:  Nazima Habibi; Saif Uddin; Montaha Behbehani; Fadila Al Salameen; Nasreem Abdul Razzack; Farhana Zakir; Anisha Shajan; Faiz Alam
Journal:  Front Microbiol       Date:  2022-07-28       Impact factor: 6.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.